Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib or acalabrutinib in select participants who have been on ibrutinib or acalabrutinib for at least

ibrutinib
acalabrutinib
gilbert's syndrome
lymphocytosis
lymphadenopathy
  • 0 views
  • 02 Jun, 2022
  • 1 location
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate

rituximab
hepatitis b core antibody
cyclin d1
lamivudine
ibrutinib
  • 51 views
  • 25 Jul, 2022
  • 8 locations
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

  • 574 views
  • 22 Jul, 2022
  • 3 locations
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP.

adenocarcinoma of prostate
adenocarcinoma
platelet count
biopsy of prostate
prostatectomy
  • 2 views
  • 01 May, 2022
  • 1 location
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

(ABC) origin. Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. We propose doing a study in which ibrutinib is combined

isavuconazole
temozolomide
aptt
ejection fraction
methotrexate
  • 18 views
  • 25 Jul, 2022
  • 1 location
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Ibrutinib, an inhibitor of Brutons tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care are

  • 0 views
  • 05 Mar, 2021
  • 9 locations
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such

constitutional symptoms
hepatitis b core antibody
beta human chorionic gonadotrophin
chronic lymphocytic leukemia
night sweats
  • 45 views
  • 17 Mar, 2022
  • 1 location
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is a Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid

beta human chorionic gonadotrophin
tumor cells
ibrutinib
progressive disease
cancer
  • 56 views
  • 08 Nov, 2020
  • 4 locations
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

This phase II trial studies the side effects and how well nivolumab and ibrutinib works in treating patients with central nervous system lymphoma that has come back or does not respond to

  • 17 views
  • 08 Feb, 2022
  • 1 location
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also

rituximab
gastric malt lymphoma
ct scan
measurable disease
  • 46 views
  • 29 Nov, 2021
  • 13 locations